Related Experiment Video
Updated: Feb 27, 2026
09:30
Author Spotlight: Microbial Control and Monitoring Strategies for Cleanroom Environments and Cellular Therapies
Published on: March 17, 2023
4.5K
Pharmaceutical Approval Update
Abstract:
Niraparib (Zejula) for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer; ocrelizumab (Ocrevus) for relapsing or primary progressive multiple sclerosis; and dupilumab (Dupixent) for moderate-to-severe atopic dermatitis.
Insights
Niraparib, ocrelizumab, and dupilumab are approved for specific cancer and autoimmune conditions. These targeted therapies offer new treatment options for ovarian cancer, multiple sclerosis, and atopic dermatitis patients.
Area of Science:
- Oncology
- Neurology
- Dermatology
Background:
- Recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer presents significant treatment challenges.
- Relapsing or primary progressive multiple sclerosis requires disease-modifying therapies.
- Moderate-to-severe atopic dermatitis impacts quality of life and necessitates effective management.
Purpose of the Study:
- To review the efficacy and safety of niraparib (Zejula) in gynecologic cancers.
- To evaluate ocrelizumab (Ocrevus) for multiple sclerosis treatment.
- To assess dupilumab (Dupixent) for atopic dermatitis management.
Main Methods:
- Clinical trial data analysis for niraparib.
- Observational studies and clinical trial reviews for ocrelizumab.
- Real-world evidence and clinical trial data for dupilumab.
Main Results:
- Niraparib demonstrates efficacy in maintaining remission for recurrent ovarian cancers.
- Ocrelizumab shows effectiveness in reducing relapses and disability progression in multiple sclerosis.
- Dupilumab significantly improves skin clearance and reduces itch in atopic dermatitis.
Conclusions:
- Niraparib provides a valuable therapeutic option for patients with recurrent gynecologic malignancies.
- Ocrelizumab is an important advancement in treating multiple sclerosis.
- Dupilumab offers a targeted approach for moderate-to-severe atopic dermatitis.
Related Concept Videos
01:26FDA Approved Drugs: Changes to Approved Drugs
292
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
292
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
54
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...
54
01:28Drug Products: Biologics, Biosimilars and Interchangeables
311
Body:Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
311
01:25Drug Regulation
3.2K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
3.2K
01:26Drug Administration and Therapy Phases: Overview
1.5K
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
1.5K
01:11Clinical Trials: Overview
5.1K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
5.1K